EN DE
Watch Myungmoon Phar for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Myungmoon Phar (017180) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Myungmoon Phar stock KRW 1,032, price KRW 1,104, that is 6.5% below the price, quality 43 out of 100. Rating: fairly valued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7017180001

MP Myungmoon Phar logo Thin data Nov 4, 2026

Myungmoon Phar

017180 · KO
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Profit last quarter +84% vs. a year ago.
Fair value 1,032 KRW · Fairly valued
Quality 43/100
Expensive Growth (revenue 5y +8.8 %/yr in KRW)
Loss over the last twelve months · -0.8% net margin (TTM) · fiscal year 2025 1.0%
Negative free cash flow
Trails peers (4/11)
Narrow moat 15/100
Thin data
Watch Myungmoon Phar for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

6,100 KRW 1,057 KRW Fair Value 1,032 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 1,057 KRW – 6,100 KRW · fair‑value band 722.43 KRW – 1,342 KRW · the 1,104 KRW price screens above the 1,032 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 4, 2026.

Follow Myungmoon Phar in your weekly email

Every Wednesday you see whether Myungmoon Phar is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally.

Show moreShow less

It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, and anti-obesity agents for pharmacotherapy.

The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, antidiarrheal agents, digestive system products, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products.

In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.

Stock analysis

Myungmoon Phar (017180) currently trades at 1,104 KRW, while our model-based Fair Value estimate is 1,032 KRW, so the stock looks roughly fairly valued today (gap 7.0%).

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 1,939 KRW per share, and 5 of the 13 models we run sit above the 1,104 KRW price.

Bear case: the Earnings-Based group reads lowest at 524.28 KRW, and 8 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: 722.43 KRW (bear) to 1,342 KRW (bull), the price of 1,104 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Myungmoon Phar reported revenue of 195B KRW in FY2025 versus 145B KRW in FY2021, a compound +7.8%/yr. Reported net income was 1.9B KRW in FY2025.

Key figures

Market cap 36.9B KRW (≈ $27.3M) Micro · P/S ratio 0.20 · EPS (TTM) −49.14 KRW · Net margin −0.8% · Return on equity −2.5% · Return on assets (EBIT) 0.8% (5-year average) · Operating margin −1.6% · Revenue (TTM) 200B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (medium confidence).

What moves the price

The share trades about 43% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −7%, 017180 screens cheaper than that median.

Fair Value models

Bear 722.43 KRW Fair Value 1,032 KRW Bull 1,342 KRW
Price 1,104 KRW · Downside -6.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 529.12 KRW 764.98 KRW 972.15 KRW 72
Residual Income 1,925 KRW 1,942 KRW 2,051 KRW 71
ROIC Compounder 529.12 KRW 764.98 KRW 972.15 KRW 71
All 14 models by family
Earnings-Based
Graham-Dodd 379.58 KRW 1,018 KRW 1,333 KRW 65
Lynch FV 198.50 KRW 283.57 KRW 368.64 KRW 61
PEG = 1.0 198.50 KRW 283.57 KRW 368.64 KRW 57
EPV 529.12 KRW 764.98 KRW 972.15 KRW 72
Multiples
P/E Multiple 921.03 KRW 1,228 KRW 1,535 KRW 63
P/S Multiple 711.71 KRW 948.94 KRW 1,186 KRW 57
P/B Multiple 2,722 KRW 3,629 KRW 4,537 KRW 55
EV/EBIT n/a 569.99 KRW 1,253 KRW 60
EV/EBITDA 503.49 KRW 1,392 KRW 2,281 KRW 62
EV/Revenue n/a n/a 553.91 KRW 49
Asset-Based
NCAV (Graham) 1,447 KRW 1,939 KRW 2,894 KRW 53
Economic Profit
Residual Income 1,925 KRW 1,942 KRW 2,051 KRW 71
ROIC Compounder 529.12 KRW 764.98 KRW 972.15 KRW 71
Growth Earnings
Growth-Adj P/E 722.43 KRW 1,032 KRW 1,342 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 36
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 23
Debt, balance sheet and risk of trouble
Investment 82
Does it invest with discipline instead of growing at any price?
Low Volatility 72
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Start year 2020 (pandemic). Over 10 years: +4.6% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−37.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−37.5%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−23% → 4%

Watch 017180, get fair value alerts →

Compare Myungmoon Phar with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Bottom 25%
Fair Value upside −6.5% · Above median
Profitability
Return on assets 0.9% · Below median
Net margin (12 months) −1.1% · Bottom 25%
Operating margin (12 months) −1.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 5.0% · Above median
Balance sheet
Debt / equity 0.43× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.37× · Cheapest 25%
P/S (12 months) 0.23× · Cheapest 25%
EV/EBITDA 17.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)25 · sector 15
FUTURE (revenue growth)25 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)78 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 017180
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 017180
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 017180
Haleon plc HLN $9.14 $8.61 −6% vs 017180
Merck KGaA MRK €148.75 €109.18 −27% vs 017180
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 017180
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 017180
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 017180
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 017180
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 017180

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Myungmoon Phar: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Myungmoon Phar Fair Value". https://www.fairvalue-calculator.com/stock/017180

Frequently asked questions

Is Myungmoon Phar (017180) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 1,032 KRW versus a price of 1,104 KRW, about 7% lower (fairly valued).
What is the fair value of 017180?
Our model-based fair value for Myungmoon Phar is 1,032 KRW (as of Nov 4, 2026), built from audited fundamentals. The current price: 1,104 KRW.
What is the quality score of 017180?
Myungmoon Phar has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Myungmoon Phar (017180)?
Our model-based price target is the fair value of 1,032 KRW (as of Nov 4, 2026) from 14 valuation models. Cautious scenario 722.43 KRW, optimistic scenario 1,342 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Myungmoon Phar stock forecast for 2026?
Our models put fair value at 1,032 KRW, about 7% lower versus a price of 1,104 KRW (fairly valued). Cautious scenario 722.43 KRW, optimistic scenario 1,342 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Myungmoon Phar (017180)?
Myungmoon Phar reported trailing-twelve-month revenue of about 200B KRW (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Myungmoon Phar (017180)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Myungmoon Phar it is 1,032 KRW per share (as of Nov 4, 2026), against a price of 1,104 KRW. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Myungmoon Phar stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 017180 trades above its calculated fair value: price 1,104 KRW, fair value 1,032 KRW, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 017180?
No. The price is what the market pays today (1,104 KRW); the fair value is what the company's own numbers justify (1,032 KRW). For Myungmoon Phar the two are 71.96 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Myungmoon Phar worth?
The market values Myungmoon Phar at about 36.9B KRW (market capitalisation, as of Nov 4, 2026). Per share that is 1,104 KRW; our models calculate a fair value of 1,032 KRW per share.
What do the bullish and bearish scenarios say about 017180?
Our models span a range for Myungmoon Phar: cautious scenario 722.43 KRW, base 1,032 KRW, optimistic 1,342 KRW per share (as of Nov 4, 2026, price 1,104 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Myungmoon Phar (017180)?
Balance-sheet figures for Myungmoon Phar (as of Nov 4, 2026): return on equity −2.5%, debt of 0.43 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 017180 from its 52-week high?
Myungmoon Phar trades at 1,104 KRW, about 43% below its 52-week high of 1,945 KRW and 4% above the low of 1,057 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,032 KRW is for.
Which stocks are comparable to Myungmoon Phar?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Myungmoon Phar stock attractive at the current price?
The data as of Nov 4, 2026: price 1,104 KRW, calculated fair value 1,032 KRW (−7%), Quality Score 43/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 017180 calculated?
We run Myungmoon Phar through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1,032 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Myungmoon Phar itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Myungmoon Phar (017180)?
The closing price on Nov 6, 2026 was 1,104 KRW. Our model-based fair value is 1,032 KRW, about 7% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Myungmoon Phar right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (722.43 KRW to 1,342 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Myungmoon Phar

How large is the market capitalisation of Myungmoon Phar (017180)?
The market capitalisation of Myungmoon Phar is 36.9B KRW (≈ $27.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Myungmoon Phar (017180)?
The price-to-sales ratio of Myungmoon Phar is 0.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Myungmoon Phar (017180)?
Earnings per share at Myungmoon Phar are −49.14 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Myungmoon Phar (017180)?
The net margin of Myungmoon Phar is −0.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Myungmoon Phar (017180)?
The return on equity (ROE) of Myungmoon Phar is −2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Myungmoon Phar (017180)?
On an EBIT basis the return on assets of Myungmoon Phar is 0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Myungmoon Phar (017180)?
The operating margin of Myungmoon Phar is −1.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Myungmoon Phar (017180)?
Revenue at Myungmoon Phar is growing +5.0% versus a year earlier (3y avg +8.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Myungmoon Phar (017180)?
Earnings per share at Myungmoon Phar are growing +83.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Myungmoon Phar (017180) generate?
The free cash flow of Myungmoon Phar is −8.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Myungmoon Phar (017180) carry?
The net debt of Myungmoon Phar is 92.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Myungmoon Phar in the live analysis

One click puts Myungmoon Phar on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.